Drug intelligence / Profile preview

ADS-02

Development stage: Preclinical
Lead developer: AdipoSeeds
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

ADS-02 is an investigational cell therapy product developed by AdipoSeeds for systemic platelet transfusion. The therapy utilizes platelet-like cells (PLCs) generated from a proprietary adipose-derived mesenchymal stem cell line (ASCL). This ASCL-PLC technology enables the large-scale, donor-independent production of functional platelets, addressing the critical shortage and logistical challenges associated with blood-banked donor platelets. ADS-02 is intended to mimic the physiological hemostatic and pro-coagulant functions of natural platelets. It is currently in preclinical development for the treatment of thrombocytopenia and other conditions requiring systemic platelet replacement.

Other names: ASCL-PLCAdipoSeeds platelet-like cells

Beyond the preview

Go deeper on ADS-02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADS-02.

Explore the full profile